Distinguished FBI and Pharmaceutical Security Expert to Lead NanoGuardian Advisory Board

SKOKIE, IL--(Marketwire - January 19, 2009) - NanoGuardian™, a division of NanoInk® that focuses on delivering brand protection solutions to fight illegal diversion and counterfeiting, is pleased to announce that John D. Glover, D.P.A., has been appointed to lead its Security Advisory Board. With a distinguished career spanning more than 35 years with the FBI, Bristol-Myers Squibb Company, the Pharmaceutical Security Institute and the U.S. State Department, Dr. Glover will advise NanoGuardian in its efforts to curb the spread of counterfeit and diverted pharmaceuticals in the supply chain.

In March 1989, Dr. Glover retired from a distinguished career with the FBI, where he investigated, supervised and managed numerous successful high-profile investigations. During his tenure, he was designated executive assistant director for administration at FBI Headquarters in Washington, D.C., one of three direct reports to the director of the FBI.

Later, Dr. Glover served as vice president, corporate security for Bristol-Myers Squibb Company. Among his many accomplishments during this timeframe, Dr. Glover was instrumental in creating the Pharmaceutical Security Institute, an industry-wide, anti-counterfeiting body. He also served as co-chairman of the U.S. State Department's Overseas Security Advisory Council.

Today, Dr. Glover serves as president of John Glover Consulting, Inc., which provides consulting services to a very select number of prominent corporate and non-governmental entities.

"After 35 years of working complex investigations, some of which included chasing counterfeiters and diverters with the FBI, NanoGuardian's on-dose NanoEncryption technology is a product that I can get excited about," said Dr. Glover. "NanoEncryption technology is the only on-dosage, multi-layered, brand protection solution that enables manufacturers to trace and authenticate every single dosage, from plant to patient."

NanoGuardian's NanoEncryption technology possesses intrinsic layered security features at the overt, covert, and forensic level and can be applied directly to tablets, capsules and vial caps. These multi-layered security features enable NanoGuardian to provide a dual-protective benefit to pharmaceutical manufacturers with a single technology. The overt and covert security features enable dose-level authentication at any point in the supply chain, while the forensic NanoCodes provide comprehensive tracing information on each and every tablet, capsule, or vial.

"Dr. Glover's experience as a security expert within the pharmaceutical industry and as the former executive assistant director for administration at the FBI makes him an invaluable resource for us as we work with the pharmaceutical industry, law enforcement, and government to stop counterfeiting and illegal diversion of pharmaceuticals," said Dean Hart, executive vice president of NanoGuardian.

Dr. Glover holds a Bachelor of Arts in Education from Florida A&M University in Tallahassee, Fla. He also received a Master and Doctorate in Public Administration from the University of Southern California.

About NanoGuardian

NanoGuardian™, a division of NanoInk®, focuses exclusively on delivering brand protection solutions to fight illegal diversion and counterfeiting. NanoGuardian's cutting-edge NanoEncryption™ technology enables manufacturers to authenticate and trace the integrity of their products across the supply chain. More information about NanoGuardian is available at www.nanoguardian.net.

Contact Information: Contacts: Joshua Taustein Dresner Corporate Services for NanoGuardian 312-780-7219 jtaustein@dresnerco.com Sara DeNio Dresner Corporate Services for NanoGuardian 312-780-7223 sdenio@dresnerco.com